What is B. Riley's Estimate for AXSM Q3 Earnings?

Key Points

• B. Riley analysts estimate Axsome Therapeutics will report a Q3 2025 earnings per share (EPS) of ($1.16), maintaining a "Buy" rating with a target price of $179.00.
• Multiple financial institutions have recently upgraded Axsome's stock, with Morgan Stanley setting a price target of $190.00 and Royal Bank of Canada raising their target to $189.00.
• Axsome reported a Q2 loss of ($0.92) EPS, exceeding consensus estimates and generating $150.04 million in revenue.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at B. Riley issued their Q3 2025 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a research report issued on Tuesday, September 30th. B. Riley analyst M. El-Saadi forecasts that the company will post earnings of ($1.16) per share for the quarter. B. Riley currently has a "Buy" rating and a $179.00 target price on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Axsome Therapeutics' Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($4.07) EPS, FY2026 earnings at $0.60 EPS, FY2027 earnings at $8.00 EPS, FY2028 earnings at $17.66 EPS and FY2029 earnings at $24.58 EPS.

AXSM has been the topic of several other reports. Morgan Stanley began coverage on shares of Axsome Therapeutics in a research report on Thursday, July 3rd. They set an "overweight" rating and a $190.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 target price on shares of Axsome Therapeutics in a report on Tuesday, June 10th. Royal Bank Of Canada lifted their price target on Axsome Therapeutics from $184.00 to $189.00 and gave the stock an "outperform" rating in a report on Tuesday, August 5th. Wells Fargo & Company raised Axsome Therapeutics to a "strong-buy" rating in a report on Wednesday, September 3rd. Finally, Bank of America lifted their target price on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating and fourteen have assigned a Buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $177.93.

Axsome Therapeutics Price Performance

Shares of AXSM opened at $119.94 on Friday. The company has a 50 day moving average of $114.55 and a 200-day moving average of $110.21. The company has a quick ratio of 1.51, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $5.99 billion, a P/E ratio of -23.66 and a beta of 0.52. Axsome Therapeutics has a twelve month low of $75.56 and a twelve month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.08. The business had revenue of $150.04 million for the quarter, compared to analyst estimates of $140.02 million. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 10,000 shares of the stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $115.96, for a total value of $1,159,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Roger Jeffs sold 13,464 shares of Axsome Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $123.68, for a total transaction of $1,665,227.52. Following the sale, the director owned 57,510 shares in the company, valued at approximately $7,112,836.80. This represents a 18.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 197,948 shares of company stock valued at $23,406,686. Corporate insiders own 22.30% of the company's stock.

Institutional Trading of Axsome Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of AXSM. GAMMA Investing LLC increased its stake in shares of Axsome Therapeutics by 38,571.9% in the first quarter. GAMMA Investing LLC now owns 22,043 shares of the company's stock valued at $2,571,000 after buying an additional 21,986 shares during the period. Rhumbline Advisers lifted its holdings in Axsome Therapeutics by 6.9% in the first quarter. Rhumbline Advisers now owns 54,760 shares of the company's stock valued at $6,387,000 after buying an additional 3,515 shares during the period. NBC Securities Inc. acquired a new position in shares of Axsome Therapeutics in the 1st quarter valued at about $31,000. Pallas Capital Advisors LLC increased its holdings in Axsome Therapeutics by 33.5% in the first quarter. Pallas Capital Advisors LLC now owns 35,280 shares of the company's stock worth $4,115,000 after purchasing an additional 8,845 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Axsome Therapeutics by 16,852.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 627,418 shares of the company's stock valued at $73,176,000 after acquiring an additional 623,717 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.